Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Common Equity (2016 - 2025)

Abeona Therapeutics has reported Common Equity over the past 15 years, most recently at $159.2 million for Q4 2025.

  • Quarterly results put Common Equity at $159.2 million for Q4 2025, up 261.6% from a year ago — trailing twelve months through Dec 2025 was $159.2 million (up 261.6% YoY), and the annual figure for FY2025 was $159.2 million, up 261.6%.
  • Common Equity for Q4 2025 was $159.2 million at Abeona Therapeutics, down from $171.2 million in the prior quarter.
  • Over the last five years, Common Equity for ABEO hit a ceiling of $171.2 million in Q3 2025 and a floor of -$8.9 million in Q1 2024.
  • Median Common Equity over the past 5 years was $41.9 million (2021), compared with a mean of $56.5 million.
  • Peak annual rise in Common Equity hit 683.75% in 2024, while the deepest fall reached 147.39% in 2024.
  • Abeona Therapeutics' Common Equity stood at $42.4 million in 2021, then plummeted by 36.84% to $26.8 million in 2022, then tumbled by 44.6% to $14.8 million in 2023, then surged by 196.99% to $44.0 million in 2024, then skyrocketed by 261.6% to $159.2 million in 2025.
  • The last three reported values for Common Equity were $159.2 million (Q4 2025), $171.2 million (Q3 2025), and $163.6 million (Q2 2025) per Business Quant data.